Sangamo Therapeutics Inc. (SGMO)

9.73
0.16 1.67
NASDAQ : Health Technology
Prev Close 9.57
Open 9.61
Day Low/High 9.57 / 9.85
52 Wk Low/High 6.26 / 19.25
Volume 944.86K
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 115.36M
Market Cap 1.15B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Here's How I Would Handle Speculative Sangamo Therapeutics

Here's How I Would Handle Speculative Sangamo Therapeutics

Let's take a look at the charts and indicators.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Brinks, Medtronic, Fiat Chrysler: 'Mad Money' Lightning Round

Brinks, Medtronic, Fiat Chrysler: 'Mad Money' Lightning Round

Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.

SGMO: Insiders Vs. Shorts

SGMO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 12/14/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 11.12 "days to cover" versus the median component at 4.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of SGMO August 16th Options Trading

First Week Of SGMO August 16th Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo Therapeutics Becomes Oversold (SGMO)

Sangamo Therapeutics Becomes Oversold (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

SGMO: Insiders Vs. Shorts

SGMO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/28/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.54 "days to cover" versus the median component at 4.65. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

First Week Of January 2021 Options Trading For Sangamo Therapeutics (SGMO)

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz

Despite $5.1 billion deal for Costa, I'm not slurping any KO up.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

Salesforce Remains a 'Go to' Name for Big Cap Momentum Players

I expect CRM to regain its footing quickly and challenge highs again soon.

HPE: Surpassing Expectations, Raising Guidance Incrementally

HPE: Surpassing Expectations, Raising Guidance Incrementally

If estimates continue to come up there will be institutional interest in the stock.

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Strength in Growth Names Is Giving the Market a More Upbeat Feel

Apple in particular is helping the bullish cause.

First Week Of SGMO September 21st Options Trading

First Week Of SGMO September 21st Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Traders Are Still Finding Plenty of Stocks That They Want to Buy

Sentiment is very positive, regardless of what the indices may say.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Interesting SGMO Put And Call Options For July 20th

Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease

Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

First Week Of SGMO June 15th Options Trading

Investors in Sangamo Therapeutics Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGMO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Market Is Finally Rewarding Stock Picking

The Market Is Finally Rewarding Stock Picking

The game plan is to spot the charts that have more room to run.

Markets Recovering From Latest Trump Tweetstorm

Markets Recovering From Latest Trump Tweetstorm

Wall Street discounting talk of bombing Syria from president.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To

4 stocks on my shopping list for when conditions improve.

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Strange: Bullish SGMO Analysts Actually See -8.91% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Sangamo Therapeutics Inc . The average 12-month price target for SGMO — averaging the work of 6 analysts — reveals an average price target of $23.50/share.

TheStreet Quant Rating: D (Sell)